Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

The company set terms for an offering with the help of a little-used section of the Securities Act that would enable its IPO ...

Anavex Life Sciences reported positive phase 2 results for ANAVEX 3-71 in schizophrenia. Read my analysis on AVXL stock here.

ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adultsOral ANAVEX®3-71 tablet ...

In September 2025, Ocuphire Pharma Inc. announced a phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose ...

Bristol Myers Squibb (BMS) plans to launch schizophrenia drug Cobenfy in the UK next year at a price matching its U.S. list price, it said on Monday.

Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development of Cobenfy (xanomeline-trospium), the first truly novel medication for ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

In two new studies, scientists at Oregon Health & Science University have uncovered detailed blueprints of how certain molecular "gates" in human cells work—findings that could open doors to new ...

A recent study found that your morning cup of coffee really does make you happier – even if you're not a caffeine addict. The study involved researchers from the University of Warwick in the United ...

The role of acetylcholine in the central and peripheral nervous systems is well established in adults. Cholinergic modulation of vascular functions and body fluid balance has been extensively studied.